Skip to main content

Philip John Walther, MD, PhD, MBA

Professor of Surgery
Associate Professor of Pathology
Division: 
Office: 1587 Hosp South, Morris Bldg, White Zone, Durham, NC 27710
Campus Mail: DUMC Box 3314 Med Ctr, Durham, NC 27710

1. DEVELOPMENTAL THERAPEUTICS OF SYSTEMIC UROLOGIC CANCER
A continuation of an ongoing effort in preclinical screening for effective new agents for the treatment of urologic malignancy-especially bladder and prostate - particular addressing issues of drug synergy.

2. p53 MUTATIONS IN PROSTATE CANCER
The presence of p53 mutations in malignancy has been considered an important genetic change in the multistep process of carcinogenesis-including radiation failure.

3. ASSOCIATION OF ONCOGENIC TYPES OF HUMAN PAPILLOMAVIRUS WITH UROLOGIC MALIGNANCY
Oncogenic types of HPV may be an important promoter-initiator of carcinogenesis in a variety of epithelia. Using polymerase chain reaction, we have analysed clinical specimens of urologic malignancy.

4. TREATMENT OF RENAL CANCER WITH GAMMA-INTERFERON
Principal Investigator (Duke site) for multi-institutional Phase II-III trial to determine the efficacy of this biologic response modifer.

5. ANDROGEN RECEPTOR-MEDIATED TRANSCRIPTIONAL REGULATION IN ANDROGEN-DEPENDENT HUMAN PROSTATE CANCER XENOGRAFT

Education and Training

  • Residency, Urologic Surgery, University of California at Los Angeles, 1977 - 1981
  • Residency, Surgery, University of California at Los Angeles, 1976 - 1977
  • Residency, Surgery, Duke University, 1975 - 1976
  • M.B.A., Duke University, 1997
  • M.D., Duke University, 1975
  • Ph.D., Duke University, 1974

Publications

Mohler, James L., Susan Halabi, Stephen T. Ryan, Ali Al-Daghmin, Mitchell H. Sokoloff, Gary D. Steinberg, Ben L. Sanford, et al. “Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series..” Prostate Cancer Prostatic Dis 22, no. 2 (May 2019): 309–16. https://doi.org/10.1038/s41391-018-0106-1.

Full Text

Ehieli, Eric I., Lauren E. Howard, Terri G. Monk, Michael N. Ferrandino, Thomas J. Polascik, Philip J. Walther, and Stephen J. Freedland. “Effect of positive end-expiratory pressure on blood loss during retropubic and robot-assisted laparoscopic radical prostatectomy..” Int J Urol 23, no. 8 (August 2016): 674–78. https://doi.org/10.1111/iju.13125.

Full Text

Bassett, Mitchell, Michael Abern, Lionel Lloyds Banez, Michael Ferrandino, Cary N. Robertson, Brant Allen Inman, Thomas Polascik, Stephen J. Freedland, Philip John Walther, and Judd W. Moul. “African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Scholars@Duke

Singh, Abhay A., Lionel Lloyds Banez, Leah Gerber, Stephen J. Freedland, Cary N. Robertson, Michael Ferrandino, Thomas Polascik, Philip John Walther, and Judd W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012. https://doi.org/10.1200/jco.2012.30.5_suppl.34.

Full Text

Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..” J Clin Oncol 30, no. 5_suppl (February 10, 2012).

Scholars@Duke

Singh, A. A., L. L. Banez, L. Gerber, S. J. Freedland, C. N. Robertson, M. Ferrandino, T. Polascik, P. J. Walther, and J. W. Moul. “Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database..” J Clin Oncol 30, no. 5_suppl (February 10, 2012). https://doi.org/10.1200/jco.2012.30.5_suppl.34.

Full Text

Klein, Eric A., Ian Thompson, Catherine M. Tangen, M Scott Lucia, Phyllis Goodman, Lori M. Minasian, Leslie G. Ford, et al. “Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..” Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 7–7. https://doi.org/10.1200/jco.2012.30.5_suppl.7.

Full Text

Klein, E. A., I. Thompson, C. M. Tangen, M. S. Lucia, P. Goodman, L. M. Minasian, L. G. Ford, et al. “Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..” J Clin Oncol 30, no. 5_suppl (February 10, 2012).

Scholars@Duke

Cotter, S. E., M. H. Chen, J. W. Moul, W. R. Lee, B. F. Koontz, M. S. Anscher, C. N. Robertson, P. J. Walther, T. J. Polascik, and A. V. D’Amico. “Re: Salvage radiation in men after prostate-specific antigen failure and the risk of death.” Journal of Urology, November 1, 2011. https://doi.org/10.1016/j.juro.2011.08.056.

Full Text

Klein, Eric A., Ian M. Thompson, Catherine M. Tangen, John J. Crowley, M Scott Lucia, Phyllis J. Goodman, Lori M. Minasian, et al. “Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)..” Jama 306, no. 14 (October 12, 2011): 1549–56. https://doi.org/10.1001/jama.2011.1437.

Full Text

Pages